These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32744950)

  • 1. Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality.
    Gertner AK; Robertson AG; Powell BJ; Jones H; Silberman P; Domino ME
    Health Aff (Millwood); 2020 Aug; 39(8):1395-1404. PubMed ID: 32744950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 3. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
    Mahone A; Enich M; Treitler P; Lloyd J; Crystal S
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):606-617. PubMed ID: 37506336
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.
    Meiselbach MK; Drake C; Saloner B; Zhu JM; Stein BD; Polsky D
    Health Aff (Millwood); 2022 Jun; 41(6):901-910. PubMed ID: 35666962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
    Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
    Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
    Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
    Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
    Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder.
    Hollander MAG; Jarlenski MP; Donohue JM; Cole ES; Kelley D; Krans EE
    Am J Obstet Gynecol; 2019 May; 220(5):502-503. PubMed ID: 30703340
    [No Abstract]   [Full Text] [Related]  

  • 16. Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
    Carney BL; Hadland SE; Bagley SM
    Pediatr Rev; 2018 Jan; 39(1):43-45. PubMed ID: 29292291
    [No Abstract]   [Full Text] [Related]  

  • 17. Opioids and Opioid Use Disorder in Pregnancy.
    Sanjanwala AR; Lim G; Krans EE
    Obstet Gynecol Clin North Am; 2023 Mar; 50(1):229-240. PubMed ID: 36822706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.
    Andraka-Christou B
    Health Aff (Millwood); 2021 Jun; 40(6):920-927. PubMed ID: 34097509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.